Clinical Trials Logo

Clinical Trial Summary

Prolactin is a hormone that naturally occurs in the body. Some women taking antipsychotic medications may have high levels of prolactin in their bodies. High levels of prolactin may cause women to have problems with sex or satisfaction from sex. It may also cause women to have fewer or no menstrual periods. It may also cause the production of breast milk and may contribute to long term bone loss.

In this study, the investigators are testing whether taking adding a low dose of an antipsychotic medication called aripiprazole may help improve high prolactin levels and help with sexual dysfunction or problems with menstrual periods. The investigators are also looking to see if it may slow the loss of bones. This medication has been shown to be helpful for improving symptoms of schizophrenia.


Clinical Trial Description

This will be a 16-week, double blind, placebo controlled randomized trial of aripiprazole added to an existing stabilized regimen of antipsychotics (either risperidone or paliperidone oral or long acting injectable formulations) for treatment of elevated symptomatic prolactin levels. Aripiprazole dosing will begin at 5 mg/day once daily and increased to 10mg by mouth once daily at the end of week 2 and then increased to 15 mg/day once daily at the end of week 8 in women who have not yet regained their menstrual period. If a woman gets her menstrual period on the 5 or 10 mg dose she will remain on this dose for the study. Women will remain on their current stabilized medication regimen during the course of the adjunctive trial of aripiprazole or placebo. Subjects will be able to receive anticholinergic medications as needed (e.g., benztropine and diphenhydramine) for extrapyramidal side effects, propranolol for akathisia, and benzodiazepines (e.g.,lorazepam) for agitation or anxiety.

Participants will be assigned to either get aripiprazole or placebo (a sugar pill), this will be decided randomly with a 50-50 chance of receiving one or the other medication. The placebo will be sucrose filled capsules that are identical to the active medication. It is double blind so no one will know if the capsule is placebo or aripiprazole. The dosing will be the exact same, one capsule taken daily until week 8. At this time 2 capsules will be given if the participant dose not regains their menstrual period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01338298
Study type Interventional
Source University of Maryland, Baltimore
Contact
Status Completed
Phase N/A
Start date January 2011
Completion date December 2016

See also
  Status Clinical Trial Phase
Completed NCT03569787 - Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire
Completed NCT02098668 - Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON N/A
Completed NCT03038308 - Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Phase 1/Phase 2
Not yet recruiting NCT00541554 - Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Phase 4
Completed NCT01270711 - Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) N/A
Completed NCT02956447 - Administration of Kisspeptin in Patients With Hyperprolactinemia Phase 2
Recruiting NCT05033119 - PROSA: Prolactin, Sex Hormones, Growth and Metabolic Biomarkers in Children and Adolescents on Antipsychotics
Completed NCT06326840 - Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment N/A
Withdrawn NCT00699530 - Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment N/A
Not yet recruiting NCT00315081 - Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Phase 3
Recruiting NCT04746313 - Prevalence of Hyperprolactinemia in Systemic Scleroderma
Terminated NCT04146389 - Hyperprolactinemia and Adrenal Steroidogenesis
Recruiting NCT00914823 - Kisspeptin Administration in the Adult Phase 1
Suspended NCT02603549 - Pituitary Function and Spontaneous Intracranial Hypotension
Completed NCT01852331 - Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia Phase 2
Completed NCT01052948 - The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events N/A
Completed NCT00436111 - Characterization of Macroprolactinemia N/A
Active, not recruiting NCT04439747 - Develop and Implement Methods for Diagnostic and Treatment of Hormonal Disorders in Patients With Chronic Kidney Disease
Recruiting NCT01742390 - A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Phase 4
Completed NCT00625950 - Endometriosis Patients Undergoing Quinagolide Treatment Phase 4